文献速递消化系统肿瘤

非热聚焦超声联合FOLFIRINOX治疗交界可切除或局部晚期胰腺癌的探索性II期试验

Non-thermal focused ultrasound with FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer: An explorative phase II trial.
PubMed 文献 · Eur J Cancer · 2026-06-20

该探索性II期试验评估了机械效应主导的非热聚焦超声(FUS)联合FOLFIRINOX方案治疗交界可切除(BRPC)或局部晚期胰腺癌(LAPC)的安全性和疗效。60例入组患者中56例完成4周期联合治疗,并与56例仅接受FOLFIRINOX的倾向评分匹配历史对照比较。结果显示联合组客观缓解率(ORR)更高(64.3% vs. 35.7%;P=0.003),中位总生存(OS)24.0 vs. 17.0个月(HR=0.63;95%CI 0.41-0.97;P=0.029),中位无进展生存(PFS)16.0 vs. 11.0个月(HR=0.65;95%CI 0.43-0.99;P=0.039),≥3级毒性发生率无显著差异(55.4% vs. 57.1%;P=0.849),且未发生FUS相关或邻近器官损伤。

要点

  • FUS联合FOLFIRINOX较单纯化疗提高ORR(64.3% vs. 35.7%)。
  • 联合组中位OS和PFS均显著延长,毒性未增加。
  • 探索性结果支持开展随机III期试验进一步验证。

核心结论

  • 在BRPC或LAPC患者中,机械效应主导的非热FUS联合FOLFIRINOX较单纯FOLFIRINOX提高了缓解率并改善了生存结局,且未增加毒性。

研究设计与样本

  • 探索性II期试验(NCT05262452),入组60例BRPC或LAPC患者,前4周期接受FUS联合FOLFIRINOX化疗,后续继续FOLFIRINOX。
  • 56例完成4周期联合治疗的患者与56例仅接受FOLFIRINOX的倾向评分匹配历史对照进行比较。

主要发现

  • 联合组ORR为64.3%,单纯化疗组为35.7%(P=0.003)。
  • 联合组中位OS为24.0个月,对照组为17.0个月(HR=0.63;95%CI 0.41-0.97;P=0.029)。
  • 联合组中位PFS为16.0个月,对照组为11.0个月(HR=0.65;95%CI 0.43-0.99;P=0.039)。
  • ≥3级毒性发生率联合组为55.4%,对照组为57.1%(P=0.849),未发生FUS相关或邻近器官损伤。

临床怎么用

  • 对于BRPC或LAPC患者,可考虑在FOLFIRINOX基础上联合非热FUS以改善缓解率和生存,但需在临床试验框架内进行。

局限性

  • 本研究为探索性II期试验,样本量有限,对照组为倾向评分匹配的历史队列,非随机对照,结论需随机III期试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: FOLFIRINOX is standard chemotherapy for borderline resectable (BRPC) or locally advanced pancreatic cancer (LAPC), but response rates remain suboptimal. Mechanical effect-dominant non-thermal focused ultrasound (FUS) may enhance drug delivery. This study prospectively evaluated the safety and efficacy of FUS plus FOLFIRINOX in patients with BRPC or LAPC. METHODOLOGY: In this exploratory phase II trial (NCT05262452), participants with BRPC or LAPC received FUS plus FOLFIRINOX chemotherapy during the first four cycles, followed by FOLFIRINOX continuation. The primary endpoint was objective response rate (ORR); secondary endpoints included overall survival (OS), progression-free survival (PFS), and treatment-related toxicity. A propensity score matched historical cohort of patients treated with FOLFIRINOX alone served as a control group. RESULTS: Of 60 enrolled patients, 56 completed four cycles of combined therapy and were matched to 56 FOLFIRINOX-only controls. ORR was higher with FUS plus FOLFIRINOX than with FOLFIRINOX alone (64.3% vs. 35.7%; P = 0.003). Median OS was 24.0 versus 17.0 months (hazard ratio [HR], 0.63; 95% CI, 0.41-0.97; P = 0.029), and median PFS was 16.0 versus 11.0 months (HR, 0.65; 95% CI, 0.43-0.99; P = 0.039) for FUS plus FOLFIRINOX and FOLFIRINOX-only groups, respectively. Grade ≥ 3 toxicities occurred in 55.4% and 57.1% of patients (P = 0.849), with no FUS-related or collateral organ injuries. DISCUSSION: Mechanical effect-dominant non-thermal FUS combined with FOLFIRINOX improved response rate and survival outcome without increasing toxicity compared with FOLFIRINOX alone in BRPC or LAPC. These exploratory findings support further evaluation in randomized phase III trials. TRIAL REGISTRATION: This study is registered at clinicaltrials.gov (study identifier: NCT05262452).

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lee DH, Lee JY, Kang SY, et al. Non-thermal focused ultrasound with FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer: An explorative phase II trial. Eur J Cancer. 2026. PMID: 42335570. doi:10.1016/j.ejca.2026.116903

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。